Oncology Corporate Profile
30.9100 | |
-0.0300 |
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. Cellectis has 17 years of expertise in gene editing based on its flagship TALENĀ® technology and pioneering electroporation system PulseAgile. This enables us to develop a new generation of immunotherapy product candidates with additional safety and efficacy attributes and equip them to resist mechanisms that inhibit immune system activity.
Website: https://www.cellectis.com/
Brand / Product | Class | Area of Study | Phase | Partnership |
---|---|---|---|---|
UCART123 | CAR T-cell therapy | Acute Myelogenous Leukemia (AML) | I | |
UCART123 | CAR T-cell therapy | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | I |